Title:
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
Document Type and Number:
Japanese Patent JP6839074
Kind Code:
B2
Abstract:
The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "NKR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
More Like This:
Inventors:
Gregory Beatty
ENGELS, Boris
Niraja Idamakanti
Carl H.JUNE
LOEW, Andreas
Michael Sea Mirone
SONG, Huijuan
Enshi Wang
WU, Qilong
ENGELS, Boris
Niraja Idamakanti
Carl H.JUNE
LOEW, Andreas
Michael Sea Mirone
SONG, Huijuan
Enshi Wang
WU, Qilong
Application Number:
JP2017514849A
Publication Date:
March 03, 2021
Filing Date:
September 17, 2015
Export Citation:
Assignee:
Novartis Age
AstraZeneca UK Limited
AstraZeneca UK Limited
International Classes:
C12N15/12; A61K35/12; A61P35/00; A61P37/04; A61P43/00; C07K14/705; C12N1/15; C12N1/19; C12N1/21; C12N5/0783; C12N5/10
Domestic Patent References:
| JP2017500869A | ||||
| JP2014507118A | ||||
| JP2001512017A |
Foreign References:
| WO2014130657A1 | ||||
| WO2013142034A1 | ||||
| WO2015142661A1 | ||||
| WO2014127261A1 | ||||
| WO2013051718A1 |
Other References:
The Journal of Immunology,2004年,Vol.172,pp.899-906
MOLECULAR THERAPY,2014年 5月 1日,Vol.22, No.SUPPL.1,p.S57, #152
Current Opinion in Immunology,2012年,Vol.24,pp.239-245
MOLECULAR THERAPY,2014年 5月 1日,Vol.22, No.SUPPL.1,p.S57, #152
Current Opinion in Immunology,2012年,Vol.24,pp.239-245
Attorney, Agent or Firm:
Mitsuo Tanaka
Hiroshi Yamazaki
Kenji Tomita
Hiroshi Yamazaki
Kenji Tomita